Minute virus of mice shows oncolytic activity against pancreatic cancer cells exhibiting a mesenchymal phenotype.

MT: Regular Issue MVMp immune mobilization mesenchymal phenotype oncolytic virus pancreatic cancer targeted virotherapy

Journal

Molecular therapy. Oncology
ISSN: 2950-3299
Titre abrégé: Mol Ther Oncol
Pays: United States
ID NLM: 9918752083706676

Informations de publication

Date de publication:
21 Mar 2024
Historique:
received: 21 04 2023
accepted: 19 02 2024
medline: 10 4 2024
pubmed: 10 4 2024
entrez: 10 4 2024
Statut: epublish

Résumé

Pancreatic cancer will soon become the second cause of death by cancer in Western countries. The main barrier to increase the survival of patients with this disease requires the development of novel and efficient therapeutic strategies that better consider tumor biology. In this context, oncolytic viruses emerge as promising therapeutics. Among them, the fibrotropic minute virus of mice prototype (MVMp) preferentially infects migrating and undifferentiated cells that highly resemble poorly differentiated, basal-like pancreatic tumors showing the worst clinical outcome. We report here that MVMp specifically infects, replicates in, and kills pancreatic cancer cells from murine and human origin with a mesenchymal, basal-like profile, while sparing cancer cells with an epithelial phenotype. Remarkably, MVMp infection, at a dose that does not provoke tumor growth inhibition in athymic mice, shows significant antitumoral effect in immune-competent models; extended mouse survival; and promoted the massive infiltration of tumors by innate, myeloid, and cytotoxic T cells that exhibit a less terminally exhausted phenotype. Collectively, we demonstrate herein for the first time that MVMp is specific and oncolytic for pancreatic tumors with mesenchymal, basal-like profile, paving the way for precision-medicine opportunities for the management of the most aggressive and lethal form of this disease.

Identifiants

pubmed: 38596307
doi: 10.1016/j.omton.2024.200780
pii: S2950-3299(24)00022-5
pmc: PMC10941004
doi:

Types de publication

Journal Article

Langues

eng

Pagination

200780

Informations de copyright

© 2024 The Author(s).

Déclaration de conflit d'intérêts

The authors declare no competing interests.

Auteurs

Margaux Vienne (M)

Centre de Recherches en Cancérologie de Toulouse, CRCT, Université de Toulouse, Inserm, CNRS, Toulouse, France.
Equipe Labellisée Fondation ARC, Paris, France.

Charlène Lopez (C)

Centre de Recherches en Cancérologie de Toulouse, CRCT, Université de Toulouse, Inserm, CNRS, Toulouse, France.
Equipe Labellisée Fondation ARC, Paris, France.

Hubert Lulka (H)

Centre de Recherches en Cancérologie de Toulouse, CRCT, Université de Toulouse, Inserm, CNRS, Toulouse, France.
Equipe Labellisée Fondation ARC, Paris, France.

Adèle Nevot (A)

Centre de Recherches en Cancérologie de Toulouse, CRCT, Université de Toulouse, Inserm, CNRS, Toulouse, France.
Equipe Labellisée Fondation ARC, Paris, France.

Guillaume Labrousse (G)

Centre de Recherches en Cancérologie de Toulouse, CRCT, Université de Toulouse, Inserm, CNRS, Toulouse, France.
Equipe Labellisée Fondation ARC, Paris, France.

Nelson Dusetti (N)

Centre de Recherche en Cancérologie de Marseille, CRCM, Inserm, CNRS, Institut Paoli-Calmettes, Université Aix-Marseille, Marseille, France.

Louis Buscail (L)

Centre de Recherches en Cancérologie de Toulouse, CRCT, Université de Toulouse, Inserm, CNRS, Toulouse, France.
Service de gastroentérologie et d'hépatologie, CHU Rangueil, Université de Toulouse, Toulouse, France.
Equipe Labellisée Fondation ARC, Paris, France.

Pierre Cordelier (P)

Centre de Recherches en Cancérologie de Toulouse, CRCT, Université de Toulouse, Inserm, CNRS, Toulouse, France.
Equipe Labellisée Fondation ARC, Paris, France.

Classifications MeSH